- Home
- NRIX vs IIIV Comparison
NRIX vs IIIV Comparison
Compare NRIX & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- IIIV
- Stock Information
- Founded
- NRIX 2009
- IIIV 2012
- Country
- NRIX United States
- IIIV United States
- Employees
- NRIX N/A
- IIIV N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- IIIV EDP Services
- Sector
- NRIX Health Care
- IIIV Technology
- Exchange
- NRIX Nasdaq
- IIIV Nasdaq
- Market Cap
- NRIX 750.4M
- IIIV 720.4M
- IPO Year
- NRIX 2020
- IIIV 2018
- Fundamental
- Price
- NRIX $12.78
- IIIV $30.89
- Analyst Decision
- NRIX Strong Buy
- IIIV Buy
- Analyst Count
- NRIX 14
- IIIV 6
- Target Price
- NRIX $26.29
- IIIV $34.33
- AVG Volume (30 Days)
- NRIX 1.7M
- IIIV 145.2K
- Earning Date
- NRIX 10-09-2025
- IIIV 11-17-2025
- Dividend Yield
- NRIX N/A
- IIIV N/A
- EPS Growth
- NRIX N/A
- IIIV N/A
- EPS
- NRIX N/A
- IIIV 5.56
- Revenue
- NRIX $83,687,000.00
- IIIV $248,271,000.00
- Revenue This Year
- NRIX $58.48
- IIIV N/A
- Revenue Next Year
- NRIX N/A
- IIIV $3.86
- P/E Ratio
- NRIX N/A
- IIIV $7.73
- Revenue Growth
- NRIX 48.32
- IIIV 25.08
- 52 Week Low
- NRIX $8.18
- IIIV $22.20
- 52 Week High
- NRIX $29.56
- IIIV $33.97
- Technical
- Relative Strength Index (RSI)
- NRIX 64.49
- IIIV 46.21
- Support Level
- NRIX $11.37
- IIIV $30.45
- Resistance Level
- NRIX $12.45
- IIIV $33.97
- Average True Range (ATR)
- NRIX 0.75
- IIIV 1.00
- MACD
- NRIX 0.20
- IIIV -0.05
- Stochastic Oscillator
- NRIX 84.06
- IIIV 25.99
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.